New CAR-T Therapy achieves positive results in a high proportion of patients with a refractory type of lymphoma

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in addition to a favorable safety profile and high in vivo persistence of CAR30+ cells.

Click here to access the article.